keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant breast

keyword
https://www.readbyqxmd.com/read/28646331/textural-features-of-18-f-fdg-pet-after-two-cycles-of-neoadjuvant-chemotherapy-can-predict-pcr-in-patients-with-locally-advanced-breast-cancer
#1
Lin Cheng, Jianping Zhang, Yujie Wang, Xiaoli Xu, Yongping Zhang, Yingjian Zhang, Guangyu Liu, Jingyi Cheng
OBJECTIVE: This study was designed to evaluate the utility of textural features for predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). METHODS: Sixty-one consecutive patients with locally advanced breast cancer underwent (18)F-FDG PET/CT scanning at baseline and after the second course of NAC. Changes to imaging parameters [maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG)] and textural features (entropy, coarseness, skewness) between the 2 scans were measured by two independent radiologists...
June 23, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28639300/multiparametric-mri-of-the-breast-a-review
#2
REVIEW
Maria Adele Marino, Thomas Helbich, Pascal Baltzer, Katja Pinker-Domenig
During their development, cancers acquire several functional capabilities, which are defined as the hallmarks of cancer. For a deeper understanding of the hallmarks of cancer, and, consequently, improved personalized patient care, diagnostic tests must be multilayered and complex to identify the relevant underlying processes of cancer development and progression. In this context, magnetic resonance imaging (MRI) has emerged as an exceptionally powerful, versatile, and precise imaging technique. MRI of the breast is an essential tool in breast imaging, with multiple indications...
June 22, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/28639030/utilization-of-hypofractionated-whole-breast-radiation-therapy-in-patients-receiving-chemotherapy-a-national-cancer-database-analysis
#3
Tejan P Diwanji, Jason K Molitoris, Arpit M Chhabra, James W Snider, Soren M Bentzen, Katherine H Tkaczuk, Paula Y Rosenblatt, Susan B Kesmodel, Emily C Bellavance, Randi J Cohen, Sally B Cheston, Elizabeth M Nichols, Steven J Feigenberg
PURPOSE: Results from four major hypofractionated whole-breast radiotherapy (HF-WBRT) trials have demonstrated equivalence in select patients with early-stage breast cancer when compared with conventionally fractionated WBRT (CF-WBRT). Because relatively little data were available on patients receiving neoadjuvant or adjuvant chemotherapy, consensus guidelines published in 2011 did not endorse the use of HF-WBRT in this population. Our goal is to evaluate trends in utilization of HF-WBRT in patients receiving chemotherapy...
June 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28638446/overexpression-of-transcobalamin-1-is-an-independent-negative-prognosticator-in-rectal-cancers-receiving-concurrent-chemoradiotherapy
#4
Yi-Ying Lee, Yu-Ching Wei, Yu-Feng Tian, Ding-Ping Sun, Ming-Jen Sheu, Ching-Chieh Yang, Li-Ching Lin, Chen-Yi Lin, Chung-Hsi Hsing, Wan-Shan Li, Chien-Feng Li, Pei-Ling Hsieh, Ching-Yih Lin
Objective: Neoadjuvant concurrent chemoradiotherapy (CCRT) is an increasingly common therapeutic strategy for locally advanced rectal cancer, but stratification of risk and final outcomes remain a major challenge. Transcobalamin 1 (TCN1), a vitamin B12 (cobalamin)-binding protein, regulates cobalamin homeostasis. High expression of TCN1 have been reported in neoplasms such as breast cancer and hepatocellular carcinoma. However, little is known about the relevance of TCN1 to rectal cancer receiving CCRT. This study examined the predictive and prognostic impact of TCN1 expression in patients with rectal cancer following neoadjuvant CCRT...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28635235/-the-role-of-postmastectomy-radiotherapy-in-clinical-t1-3n1m0-breast-cancer-patients-with-pathological-negative-lymph-nodes-after-neoadjuvant-chemotherapy-and-mastectomy
#5
Q L Rong, S L Wang, Y Tang, J Jin, Y W Song, W H Wang, Y P Liu, H Fang, H Ren, X F Liu, Z H Yu, Y X Li
Objective: To analyze the outcomes of clinical T1-3N1M0 breast cancer patients with pathological negative axillary lymph nodes (ypN0) after neoadjuvant chemotherapy (NAC) and mastectomy, and investigate the role of postmastectomy radiotherapy (PMRT). Methods: A total of 185 patients with clinical T1-3N1M0 breast cancer treated between 1999 and 2013 were retrospectively reviewed. All patients were treated with NAC and mastectomy, and achieved ypN0. Of them, 89 patients received additional PMRT and 96 patients did not...
June 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28627463/pre-operative-assessment-of-residual-disease-in-locally-advanced-breast-cancer-patients-a-sequential-study-by-quantitative-diffusion-weighted-mri-as-a-function-of-therapy
#6
Khushbu Agarwal, Uma Sharma, Rani G Sah, Sandeep Mathur, Smriti Hari, Vurthaluru Seenu, Rajinder Parshad, Naranamangalam R Jagannathan
PURPOSE: The potential of diffusion weighted imaging (DWI) in assessing pathologic response and surgical margins in locally advanced breast cancer patients (n=38) undergoing neoadjuvant chemotherapy was investigated. METHODS: DWI was performed at pre-therapy (Tp0), after I (Tp1) and III (Tp3) NACT at 1.5T. Apparent diffusion coefficient (ADC) of whole tumor (ADCWT), solid tumor (ADCST), intra-tumoral necrosis (ADCNec) was determined. Further, ADC of 6 consecutive shells (5mm thickness each) including tumor margin to outside tumor margins (OM1 to OM5) was calculated and the data analyzed to define surgical margins...
June 13, 2017: Magnetic Resonance Imaging
https://www.readbyqxmd.com/read/28624524/a-direct-comparison-of-porcine-strattice%C3%A2-and-bovine-surgimend%C3%A2-acellular-dermal-matrices-in-implant-based-immediate-breast-reconstruction
#7
Jessica F Ball, Yezen Sheena, Dina M Tarek Saleh, Parto Forouhi, Sarah L Benyon, Michael S Irwin, Charles M Malata
INTRODUCTION: Acellular dermal matrix (ADM) assisted implant-based breast reconstruction (IBBR) has grown in popularity over traditional submuscular techniques. Numerous human, bovine or porcine derived ADMs are available with the type used varying considerably worldwide. Yet, comparative evidence for the efficacy of different ADMs particularly xenogenic is limited. This study directly compares early outcomes of porcine (Strattice™) and bovine (Surgimend™) ADMs in IBBR. METHOD: Retrospective study of sequential experience of immediate IBBR using Strattice or Surgimend ADM...
May 19, 2017: Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS
https://www.readbyqxmd.com/read/28624359/new-challenges-in-multimodal-workout-of-locally-advanced-breast-cancer
#8
REVIEW
Alejandro Martin Sanchez, Gianluca Franceschini, Armando Orlandi, Alba Di Leone, Riccardo Masetti
The term "locally advanced breast cancer" (LABC) encompasses a heterogeneous group of breast neoplasms that represent an extremely variable percentage of newly diagnosed breast cancers (4-90%, depending of world regions). These cancers may have different clinical and biological characteristics that can be managed by primary surgery or neoadjuvant integrated treatments. In this paper we review the updated guidelines and discuss most recently reported evidence related to LABC multidisciplinary workout, in order to maximize results of combined systemic therapies, modern surgical procedures and radiotherapy...
June 14, 2017: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
https://www.readbyqxmd.com/read/28621239/a-microrna-signature-associated-with-pathological-complete-response-to-novel-neoadjuvant-therapy-regimen-in-triple-negative-breast-cancer
#9
Raúl García-Vazquez, Erika Ruiz-García, Abelardo Meneses García, Horacio Astudillo-de la Vega, Fernando Lara-Medina, Alberto Alvarado-Miranda, Héctor Maldonado-Martínez, Juan A González-Barrios, Alma D Campos-Parra, Sergio Rodríguez Cuevas, Laurence A Marchat, César López-Camarillo
Neoadjuvant chemotherapy aims to improve the outcome of breast cancer patients, but only few would benefit from this treatment. Pathological complete response has been proposed as a surrogate marker for the prediction of long-term clinical benefits; however, 50%-85% patients have an unfavorable pathological complete response to chemotherapy. MicroRNAs are known biomarkers of breast cancer progression; nevertheless, their potential to identify patients with pathological complete response remains poorly understood...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28621233/plasma-fibrinogen-level-may-be-a-possible-marker-for-the-clinical-response-and-prognosis-of-patients-with-breast-cancer-receiving-neoadjuvant-chemotherapy
#10
Yu Mei, Haixia Liu, Xiaorong Sun, Xiangyi Li, Song Zhao, Rong Ma
Neoadjuvant chemotherapy has been established as standard treatments for advanced breast cancer among multidisciplinary therapies. A simple and instructive biomarker for the postoperative recurrence and metastasis is needed to evaluate the therapeutic effect. Plasma fibrinogen level has been shown to be associated with tumor progression and poor outcomes in breast cancer patients. This study aims to further evaluate the clinical and prognostic value of plasma fibrinogen level as a biomarker in breast cancer patients receiving neoadjuvant chemotherapy...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28621227/expression-of-epithelial-mesenchymal-transition-driver-brachyury-and-status-of-tumor-infiltrating-cd8-and-foxp3-lymphocytes-in-predicting-treatment-responses-to-neoadjuvant-chemotherapy-of-breast-cancer
#11
Kwan Ho Lee, Eun Young Kim, Yong Lai Park, Sung-Im Do, Seoung Wan Chae, Chan Heun Park
Brachyury has been characterized as a driver of epithelial-mesenchymal transition process which is regarded as an important mechanism of cancer cell invasion and metastatic progression. The status of tumor-infiltrating lymphocytes has been proposed to predict response to neoadjuvant chemotherapy in breast cancer. We investigated the clinical significance and value of tumor-infiltrating lymphocytes and brachyury as biomarkers to predict treatment responses to neoadjuvant chemotherapy in breast cancer. We also examined the correlation of the Neo-Bioscore with tumor-infiltrating lymphocytes and brachyury to indirectly predict long-term outcome...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28618304/breast-magnetic-resonance-imaging-use-in-patients-undergoing-neoadjuvant-chemotherapy-is-associated-with-less-mastectomies-in-large-ductal-cancers-but-not-in-lobular-cancers
#12
Ingeborg J H Vriens, Kristien Keymeulen, Marc B I Lobbes, Annelotte C M van Bommel, Grard A P Nieuwenhuijzen, Marjolein L Smidt, Liesbeth J Boersma, Thijs van Dalen, Carolien H Smorenburg, Henk Struikmans, Sabine Siesling, Adri C Voogd, Vivianne C G Tjan-Heijnen
BACKGROUND: To assess the impact of breast magnetic resonance imaging (MRI) use on surgical outcome per histological breast cancer subtype in patients treated with neoadjuvant chemotherapy. PATIENTS AND METHODS: All patients aged 18-70 years who underwent neoadjuvant chemotherapy for stage I-III invasive breast cancer in the Netherlands in the years 2011-2013 were identified from the Netherlands Cancer Registry. Patients with cT4 tumours were excluded from the analysis...
June 12, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28616845/neoadjuvant-therapy-for-breast-cancer-established-concepts-and-emerging-strategies
#13
REVIEW
Tessa G Steenbruggen, Mette S van Ramshorst, Marleen Kok, Sabine C Linn, Carolien H Smorenburg, Gabe S Sonke
In the last decade, the systemic treatment approach for patients with early breast cancer has partly shifted from adjuvant treatment to neoadjuvant treatment. Systemic treatment administration started as a 'one size fits all' approach but is currently customized according to each breast cancer subtype. Systemic treatment in a neoadjuvant setting is at least as effective as in an adjuvant setting and has several additional advantages. First, it enables response monitoring and provides prognostic information; second, it downstages the tumor, allowing for less extensive surgery, improved cosmetic outcomes, and reduced postoperative complications such as lymphedema; and third, it enables early development of new treatment strategies by using pathological complete remission as a surrogate outcome of event-free and overall survival...
June 14, 2017: Drugs
https://www.readbyqxmd.com/read/28615970/changes-in-pulmonary-function-tests-in-breast-carcinoma-patients-treated-with-locoregional-post-mastectomy-radiotherapy-results-of-a-pilot-study
#14
Eyad Fawzi AlSaeed, Faisal Khalid Balaraj, Mutahir A Tunio
BACKGROUND: The aim of present pilot study was to evaluate the changes in pulmonary function tests (PFTs) after locoregional post-mastectomy radiotherapy (PMRT) in breast cancer patients. MATERIALS AND METHODS: Twenty consecutive patients with histopathologically confirmed breast carcinoma stages T1-T4, N1-N2, who were treated with modified radical mastectomy with neoadjuvant or adjuvant chemotherapy underwent PFTs, including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), forced expiratory flow at 50%, and peak expiratory flow rate, maximum mid expiratory flow (MMEF25-75), maximal oxygen consumption (VO2max), and carbon monoxide diffusing capacity (DLCO) before, at 30 days, and at 90 days after locoregional PMRT...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28612227/development-of-a-ki-67-based-clinical-trial-assay-for-neoadjuvant-endocrine-therapy-response-monitoring-in-breast-cancer
#15
Rodrigo Goncalves, Katherine DeSchryver, Cynthia Ma, Yu Tao, Jeremy Hoog, Maggie Cheang, Erika Crouch, Neha Dahiya, Souzan Sanati, Michael Barnes, Luis Otávio Zanatta Sarian, John Olson, Donald Craig Allred, Matthew J Ellis
PURPOSE: The recent publication of the ACOSOG Z1031 trial results demonstrated that Ki-67 proliferation marker-based neoadjuvant endocrine therapy response monitoring could be used for tailoring the use of adjuvant chemotherapy in ER+HER2-negative breast cancer patients. In this paper, we describe the development of the Ki-67 clinical trial assay used for this study. METHODS: Ki-67 assay assessment focused on reproducing a 2.7% Ki-67 cut-point (CP) required for calculating the Preoperative Endocrine Prognostic Index and a 10% CP for poor endocrine therapy response identification within the first month of neoadjuvant endocrine treatment...
June 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28611541/effectiveness-of-pertuzumab-trastuzumab-and-docetaxel-combination-neoadjuvant-chemotherapy-for-her2-positive-inflammatory-breast-cancer-a-case-report
#16
Yuji Yamashita, Yuko Tanaka, Seishi Kono, Meiko Nishimura, Toru Mukohara, Yukiko Morinaga, Shigeo Hara, Shintaro Takao
BACKGROUND: Inflammatory breast cancer (IBC) is the most aggressive form of primary breast cancer. CASE REPORT: A 40-year-old woman was referred to our hospital for evaluation of an induration in the right breast, suspected to be breast cancer. The tumor was diagnosed as estrogen receptor-negative, progesterone receptor-negative, HER2-positive, T4dN3cM0 stage IIIc IBC with axillary lymph node metastasis. Rather than surgical intervention, we chose a systemic treatment approach with pertuzumab, trastuzumab, and docetaxel (PTD) combination therapy which was shown to be effective for HER2-positive IBC in the NeoSphere trial...
March 2017: Breast Care
https://www.readbyqxmd.com/read/28611275/predictive-factors-of-pathologic-complete-response-in-her2-positive-and-axillary-lymph-node-positive-breast-cancer-after-neoadjuvant-paclitaxel-carboplatin-plus-with-trastuzumab
#17
Jinhua Ding, Yinlong Yang, Li Jiang, Weizhu Wu, Zhiming Shao
OBJECTIVE: This study was performed to investigate the proportion as well as the predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab (PCH). RESULTS: The pCR rate in the breast, axilla and both was 44.3% (39/88), 47.7% (42/88) and 34.1% (30/88), respectively. Patients with and without pCR were similar in term of age, BMI, menstrual status, family history, treatment cycles and tumor characteristics (laterality and size of tumor)...
May 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28611109/an-in-vivo-functional-screen-identifies-jnk-signaling-as-a-modulator-of-chemotherapeutic-response-in-breast-cancer
#18
Matthew Ashenden, Antoinette van Weverwijk, Nirupa Murugaesu, Antony Fearns, James Campbell, Qiong Gao, Marjan Iravani, Clare M Isacke
Chemotherapy remains the mainstay of treatment for advanced breast cancer, however, resistance is an inevitable event for the majority of patients with metastatic disease. Moreover, there is little information available to guide stratification of first line chemotherapy, crucial given the common development of multidrug resistance. Here we describe an in vivo screen to interrogate the response to anthracycline-based chemotherapy in a syngeneic metastatic breast cancer model, and identify JNK signaling as a key modulator of chemotherapy response...
June 13, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28608612/factors-impacting-the-accuracy-of-intra-operative-evaluation-of-sentinel-lymph-nodes-in-breast-cancer
#19
Catherine L Akay, Constance Albarracin, Tiffany Torstenson, Roland Bassett, Elizabeth A Mittendorf, Min Yi, Henry M Kuerer, Gildy V Babiera, Isabelle Bedrosian, Kelly K Hunt, Rosa F Hwang
Sentinel lymph node dissection (SLND) is a standard axillary staging technique in breast cancer and intraoperative sentinel lymph node (SLN) assessment is important for decision-making regarding additional treatment and reconstruction. This study was undertaken to investigate clinicopathologic factors impacting the accuracy of intraoperative SLN evaluation. Records of patients with clinically node-negative, invasive breast cancer who underwent SLND with frozen section intraoperative pathologic evaluation from 2004 to 2007 were reviewed...
June 13, 2017: Breast Journal
https://www.readbyqxmd.com/read/28604321/sentinel-lymph-node-biopsy-and-neoadjuvant-chemotherapy-in-the-management-of-early-breast-cancer-safety-considerations-and-timing
#20
Jenny Edge, Sarah Nietz
Over the last decades, breast cancer treatment has become more personalised. Treatment plans are based on the biology of the tumour rather than the stage. Consequently, neoadjuvant chemotherapy (NACT) is commonly the primary therapy for early breast cancer as well as locally advanced disease. Sentinel lymph node biopsy (SLNB) is standard axillary management for women with node-negative disease. This review looks at the relevant literature and gives guidance on the timing of SLNB when NACT is planned and evaluates the safety of performing an SLNB rather than an axillary clearance...
May 24, 2017: South African Medical Journal, Suid-Afrikaanse Tydskrif Vir Geneeskunde
keyword
keyword
72735
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"